皮下特异性免疫治疗儿童慢性变态反应性鼻-鼻窦炎对视觉模拟量表评分和Lund-Kennedy鼻内镜评分的影响  

Effects of Subcutaneous Specific Immunotherapy on Visual Analog Scale Score and Lund-Kennedy Nasal Endoscopy Score in Children with Chronic Allergic Rhinosinusitis

作　　者：陈霞[1] 张飞[1] 舒俊华[1] Chen Xia;Zhang Fei;Shu Junhua(Maternity and Child Healthcare Hospital of Hubei,Wuhan 430070,China)

机构地区：[1]湖北省妇幼保健院,武汉430070

出　　处：《儿科药学杂志》2022年第2期46-48,共3页Journal of Pediatric Pharmacy

摘　　要：目的:探讨皮下特应性免疫治疗儿童慢性变态反应性鼻-鼻窦炎的长期疗效。方法:选取2015年6月至2016年6月于我院过敏门诊确诊的慢性鼻-鼻窦炎且皮肤点刺试验螨阳性(++及以上)患儿60例,年龄5~14岁,随机分为对照组和观察组各30例。对照组患儿接受常规治疗如局部糖皮质激素、抗过敏药物、必要的抗菌药物及鼻腔冲洗等;观察组患儿在常规治疗的基础上予以标准化螨变应原制剂进行皮下免疫治疗。采用视觉模拟量表(VAS)评分和Lund-Kennedy鼻内镜评分于治疗前及治疗1年、2年和3年时对两组患儿进行评估。结果:两组患儿治疗前VAS评分及Lund-Kennedy评分比较差异均无统计学意义(P>0.05)。对照组治疗前、治疗1年、2年和3年的VAS评分及Lund-Kennedy评分比较差异均无统计学意义(P>0.05);观察组治疗1年、2年和3年VAS评分及Lund-Kennedy评分均低于治疗前(P<0.01),且均低于同时期的对照组(P<0.01)。结论:皮下特异性免疫治疗可减轻鼻腔局部的炎症反应,阻止儿童变态反应性慢性鼻-鼻窦炎复发,改善预后,长期疗效稳定,是值得推荐的治疗方法。Objective: To probe into the long-term efficacy of subcutaneous specific immunotherapy in children with chronic allergic rhinosinusitis. Methods: Children aged from 5 to 14 years with chronic rhinosinusitis and skin prick test mite positive(++ and above) diagnosed in allergy clinic of Maternity and Child Healthcare Hospital of Hubei from Jun. 2015 to Jun. 2016 were extracted to be randomly divided into the control group and the observation group, with 30 cases in each group. The control group received routine treatment such as local glucocorticoids, antiallergic drugs, necessary antibiotics and nasal irrigation, while the observation group was given standardized mite allergen preparation for subcutaneous specific immunotherapy on the basis of routine treatment. Visual analogue scale(VAS) score and Lund-Kennedy nasal endoscopy score were used for evaluation in two groups before treatment and after treatment of 1, 2 and 3 years. Results: There was no statistically significant difference in VAS score and Lund-Kennedy score between two groups before treatment(P>0.05). There was no significant difference in VAS score and Lund-Kennedy score in the control group before treatment and after treatment of 1, 2 and 3 years(P>0.05). VAS score and Lund-Kennedy score decreased significantly after treatment of 1, 2 and 3 years compared with those before treatment in the observation group(P<0.01), and were significant lower than those of the control group during the same period(P<0.01). Conclusion: Subcutaneous specific immunotherapy can reduce the local inflammatory response in nasal cavity, prevent the recurrence of chronic allergic rhinosinusitis in children, improve the prognosis, and have stable long-term efficacy, which is a recommended treatment method.

关 键 词：慢性鼻-鼻窦炎 儿童 螨过敏 皮下特异性免疫治疗 

分 类 号：R725.6[医药卫生—儿科]